

REMARKS

In response to the restriction requirement under reply, Applicant has elected proteasome inhibitor species bortezomib and the polymer species acrylic polymers and copolymers without traverse. Claims 1-8 and 10-25 read thereon. However, the Applicant disagrees with the Examiner's request that he elect a species of both a C-terminal peptide aldehyde and a proteasome inhibitor. C-terminal peptide aldehydes are proteasome inhibitors (see, e.g., claim 7). Therefore, Applicant has elected one species, bortezomib, which is a boronic acid, from the entire group of disclosed proteasome inhibitors.

The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 01-2525. If the Examiner feels that a telephone conference would in any way expedite the prosecution of the application, please do not hesitate to call the undersigned at telephone (707) 543-5021.

Respectfully submitted,

/Alan M. Krubiner, Registration No. 26,289/

Alan M. Krubiner
Registration No. 26,289
Attorney for Applicant

Medtronic Vascular, Inc.
3576 Unocal Place
Santa Rosa, CA 95403
Facsimile No.: (707) 543-5420